银屑病与STAT3

doi:10.3760/cma.j.issn.0412-4030.2019.07.014

摘要/Abstract

摘要： 【摘要】银屑病是一种慢性炎症性皮肤病，其发病机制尚不明确，目前认为由遗传、环境、免疫等共同介导。信号转导与转录激活因子3（STAT3）是一种重要的转录因子，与肿瘤、自身免疫性疾病等相关，通过参与Th17细胞分化、角质形成细胞过度增生与异常分化、与炎症细胞相互作用、真皮血管增生等重要病理过程在银屑病发病中起关键作用。近年来，针对STAT3及其上游JAK激酶治疗银屑病的研究显示出较好的有效性和安全性。本文就银屑病与STAT3的关系进行综述，为以STAT3为靶点治疗银屑病的可行性提供依据。

关键词: 银屑病, STAT3转录因子, Janus激酶类, 角蛋白细胞, 发病机制, 治疗

Abstract: 【Abstract】 Psoriasis is a chronic inflammatory skin disease. Its pathogenesis remains unclear, and is currently considered to be co-mediated by heredity, environment and immunity. Signal transducer and activator of transcription 3 （STAT3） is an important transcription factor, which is associated with cancer and autoimmune diseases. STAT3 plays a crucial role in the occurrence of psoriasis by participating in the differentiation of T helper 17 cells, hyperproliferation and abnormal differentiation of keratinocytes, interaction with inflammatory cells, hyperplasia of dermal vessels and other important pathological processes. In recent studies, therapies targeting STAT3 and its upstream Janus kinases （JAK） have shown good efficacy and safety in the management of psoriasis. This review summarizes the association between psoriasis and STAT3, so as to provide evidence for the feasibility of the treatment of psoriasis with targeted inhibition of STAT3.

Key words: Psoriasis, STAT3 transcription factor, Janus kinases, Keratinocytes, Pathogenesis, Therapy

陈怡雯苏婷苏忠兰. 银屑病与STAT3[J]. 中华皮肤科杂志, 2019, 52(7): 502-505.

Chen Yiwen, Su Ting, Su Zhonglan. Association between psoriasis and STAT3[J]. Chinese Journal of Dermatology, 2019, 52(7): 502-505.

参考文献 33

［1］	Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology［J］. J Am Acad Dermatol, 2017,76（3）:377⁃390. doi: 10.1016/j.jaad.2016.07.064.
［2］	Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities［J］. Dermatol Clin, 2015,33（1）:41⁃55. doi: 10.1016/j.det.2014.09.004.
［3］	Parisi R, Webb RT, Kleyn CE, et al. Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study［J］. Br J Dermatol, 2019,180（1）:108⁃115. doi: 10.1111/bjd.17004.
［4］	Kamstrup MR, Skov L, Zachariae C, et al. Psoriasis and risk of malignant lymphoma: a population⁃based cohort study［J］. Br J Dermatol, 2018,178（6）:1435⁃1436. doi: 10.1111/bjd.16245.
［5］	Eppinga H, Poortinga S, Thio HB, et al. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease［J］. Inflamm Bowel Dis, 2017,23（10）:1783⁃1789. doi: 10.1097/MIB.0000000000001169.
［6］	Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model［J］. Nat Med, 2005,11（1）:43⁃49. doi: 10.1038/nm1162.
［7］	Albanesi C, Madonna S, Gisondi P, et al. The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis［J］. Front Immunol, 2018,9:1549. doi: 10.3389/fimmu. 2018.01549.
［8］	蔡明龙, 王文俊, 张学军. 银屑病全基因组关联分析与精准医学［J］. 中华皮肤科杂志, 2018,51（10）:715⁃719. doi: 10.3760/cma.j.issn.0412⁃4030.2018.10.002.
［9］	Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review［J］. J Autoimmun, 2015,64:66⁃73. doi: 10.1016/j.jaut.2015.07.008.
［10］	Zeng J, Luo S, Huang Y, et al. Critical role of environmental factors in the pathogenesis of psoriasis［J］. J Dermatol, 2017,44（8）:863⁃872. doi: 10.1111/1346⁃8138.13806.
［11］	Jin L, Wang G. Keratin 17: a critical player in the pathogenesis of psoriasis［J］. Med Res Rev, 2014,34（2）:438⁃454. doi: 10.1002/ med.21291.
［12］	Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T⁃cell autoantigen in psoriasis［J］. Nat Commun, 2014,5:5621. doi: 10.1038/ncomms6621.
［13］	Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin⁃36 signalling in plaque psoriasis and pustular psoriasis［J］. Acta Derm Venereol, 2018,98（1）:5⁃13. doi: 10.2340/00015555⁃2808.
［14］	王刚. 中性粒细胞：银屑病研究新热点［J］. 中华皮肤科杂志, 2018,51（10）:711⁃714. doi: 10.3760/cma.j.issn.0412⁃4030.2018. 10.001.
［15］	Darnell JE. STATs and gene regulation［J］. Science, 1997,277（5332）:1630⁃1635.
［16］	Hillmer EJ, Zhang H, Li HS, et al. STAT3 signaling in immunity［J］. Cytokine Growth Factor Rev, 2016,31:1⁃15. doi: 10.1016/j.cytogfr.2016.05.001.
［17］	Mertens C, Darnell JE. SnapShot: JAK⁃STAT signaling［J］. Cell, 2007,131（3）:612. doi: 10.1016/j.cell.2007.10.033.
［18］	Yu H, Lee H, Herrmann A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions［J］. Nat Rev Cancer, 2014,14（11）:736⁃746. doi: 10.1038/nrc3818.
［19］	Timofeeva OA, Chasovskikh S, Lonskaya I, et al. Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA［J］. J Biol Chem, 2012,287（17）:14192⁃14200. doi: 10. 1074/jbc.M111.323899.
［20］	Bromberg J. Stat proteins and oncogenesis［J］. J Clin Invest, 2002,109（9）:1139⁃1142. doi: 10.1172/JCI15617.
［21］	Camporeale A, Poli V. IL⁃6, IL⁃17 and STAT3: a holy trinity in auto⁃immunity?［J］. Front Biosci （Landmark Ed）, 2012,17:2306⁃2326.
［22］	Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases［J］. Cytokine, 2009,47（3）:149⁃156. doi: 10.1016/j.cyto.2009.07.003.
［23］	Zheng Y, Danilenko DM, Valdez P, et al. Interleukin⁃22, a T（H）17 cytokine, mediates IL⁃23⁃induced dermal inflammation and acanthosis［J］. Nature, 2007,445（7128）:648⁃651. doi: 10.1038/nature05505.
［24］	Zhang B, Xie S, Su Z, et al. Heme oxygenase⁃1 induction attenuates imiquimod⁃induced psoriasiform inflammation by negative regulation of Stat3 signaling［J］. Sci Rep, 2016,6:21132. doi: 10.1038/srep21132.
［25］	Shi X, Jin L, Dang E, et al. IL⁃17A upregulates keratin 17 in keratinocytes through STAT1⁃ and STAT3⁃dependent mechanisms［J］. J Invest Dermatol, 2011,131（12）:2401⁃2408. doi: 10.1038/jid.2011.222.
［26］	Müller A, Hennig A, Lorscheid S, et al. IκBζ is a key transcriptional regulator of IL⁃36⁃driven psoriasis⁃related gene in keratinocytes［J］. Proc Natl Acad Sci U S A, 2018,115（40）:10088⁃10093. doi: 10.1073/pnas.1801377115.
［27］	Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis［J］. Blood, 2003,102（1）:161⁃168. doi: 10.1182/blood⁃2002⁃12⁃3793.
［28］	Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up⁃regulates VEGF and tumor angiogenesis［J］. Oncogene, 2002,21（13）:2000⁃2008. doi: 10.1038/sj.onc.1205260.
［29］	Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA⁃21, a Stat3 inhibitor［J］. J Invest Dermatol, 2011,131（1）:108⁃117. doi: 10.1038/jid.2010.255.
［30］	Xu Y, Ji Y, Lan X, et al. miR⁃203 contributes to IL⁃17⁃induced VEGF secretion by targeting SOCS3 in keratinocytes［J］. Mol Med Rep, 2017,16（6）:8989⁃8996. doi: 10.3892/mmr.2017.7759.
［31］	Yan JJ, Qiao M, Li RH, et al. Downregulation of miR⁃145⁃5p contributes to hyperproliferation of keratinocytes and skin inflammation in psoriasis［J］. Br J Dermatol, 2019,180（2）:365⁃372. doi: 10.1111/bjd.17256.
［32］	Valenzuela F, Korman NJ, Bissonnette R, et al. Tofacitinib in patients with moderate⁃to⁃severe chronic plaque psoriasis: long⁃term safety and efficacy in an open⁃label extension study［J］. Br J Dermatol, 2018,179（4）:853⁃862. doi: 10.1111/bjd.16798.
［33］	Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: a review of applications in dermatology［J］. J Am Acad Dermatol, 2018,79（3）:535⁃544. doi: 10.1016/j.jaad.2018. 04.018.

[1]	沈佳元慧杰潘萌. 嗜酸性粒细胞在大疱性类天疱疮发病机制中的作用[J]. 中华皮肤科杂志, 2019, 52(8): 579-581.
[2]	梁源刘玲玲王珊赵作涛马琳向欣顾恒陈崑王华易红陈谨萍张金桃姚志荣郭一峰陈戟程颖朱学骏. 0.03%他克莫司软膏长期间歇维持治疗儿童特应性皮炎的多中心随机对照临床研究[J]. 中华皮肤科杂志, 2019, 52(8): 519-524.
[3]	路坦王珊王榴慧李萍舒虹申春平吴瑶罗珍缪丽敏王红兵焦磊田晶彭晓霞赵牧童刘盈聂晓璐马琳何黎. 一种含青刺果油等提取物的润肤剂改善儿童特应性皮炎缓解期临床症状的多中心、随机、平行对照临床研究[J]. 中华皮肤科杂志, 2019, 52(8): 537-541.
[4]	李凌佳刘彤云. 胱天蛋白酶14在慢性光化性皮炎患者皮损中的表达及中波紫外线对其mRNA和蛋白在HaCaT细胞中表达的影响[J]. 中华皮肤科杂志, 2019, 52(7): 486-490.
[5]	苏蓓蓓甘泉甘才斌. 二甲双胍对银屑病样小鼠模型皮损炎症状态及磷酸化Stat3蛋白表达的影响[J]. 中华皮肤科杂志, 2019, 52(7): 475-480.
[6]	卢旭亚徐强李品川张朝晖. 下肢痛性溃疡诊疗进展[J]. 中华皮肤科杂志, 2019, 52(7): 510-514.
[7]	覃慧郑捷. 鞘氨醇1-磷酸盐受体拮抗剂（FTY720）抑制皮肤中分泌白细胞介素17的γδT细胞治疗银屑病的机制研究[J]. 中华皮肤科杂志, 2019, 52(6): 395-400.
[8]	王丽玮罗玲玲崔盘根李岷. 肠道菌群与银屑病关系的研究进展[J]. 中华皮肤科杂志, 2019, 52(5): 357-360.
[9]	余丽娟吕中法. JAK抑制剂治疗斑秃的研究进展[J]. 中华皮肤科杂志, 2019, 52(5): 343-346.
[10]	胡煜陈敏顾恒. microRNA和lncRNA在银屑病中的研究进展[J]. 中华皮肤科杂志, 2019, 52(5): 350-353.
[11]	潘家旭周婧. 核因子κB信号通路在银屑病中的研究进展[J]. 中华皮肤科杂志, 2019, 52(5): 361-363.
[12]	寿艳红张臻骆肖群陈圣安李峰朱小华林尽染秦海红杜鹃陈荪奕杨永生徐金华. 干扰素γ和TRAIL联合对HaCaT细胞程序性坏死的影响及机制研究[J]. 中华皮肤科杂志, 2019, 52(5): 302-309.
[13]	周园陈韡王大光. 钳形甲的治疗进展[J]. 中华皮肤科杂志, 2019, 52(5): 364-367.
[14]	曾菁莘田歆朱慧兰张锡宝林玲张丽丹刘炜钰罗权. 微小RNA-148a-3p在寻常型银屑病患者外周血CD4⁺ T淋巴细胞中的表达及临床意义[J]. 中华皮肤科杂志, 2019, 52(4): 231-235.
[15]	罗金成陈曙光刘文英徐艳宋志强. 自体全血注射对自体血清皮肤试验阳性的难治性慢性自发性荨麻疹患者嗜碱性粒细胞FcεRⅠ与CD63表达的影响[J]. 中华皮肤科杂志, 2019, 52(4): 241-247.